PT  - JOURNAL ARTICLE
AU  - Melissa T Carter
AU  - Myriam Srour
AU  - Ping-Yee Billie Au
AU  - Daniela Buhas
AU  - Sarah Dyack
AU  - Alison Eaton
AU  - Michal Inbar-Feigenberg
AU  - Heather Howley
AU  - Anne Kawamura
AU  - Suzanne M E Lewis
AU  - Elizabeth McCready
AU  - Tanya N Nelson
AU  - Hilary Vallance
ED  - ,
TI  - Genetic and metabolic investigations for neurodevelopmental disorders: position statement of the Canadian College of Medical Geneticists (CCMG)
AID  - 10.1136/jmg-2022-108962
DP  - 2023 Feb 23
TA  - Journal of Medical Genetics
PG  - jmg-2022-108962
4099  - http://jmg.bmj.com/content/early/2023/03/07/jmg-2022-108962.short
4100  - http://jmg.bmj.com/content/early/2023/03/07/jmg-2022-108962.full
AB  - Purpose and scope The aim of this position statement is to provide recommendations for clinicians regarding the use of genetic and metabolic investigations for patients with neurodevelopmental disorders (NDDs), specifically, patients with global developmental delay (GDD), intellectual disability (ID) and/or autism spectrum disorder (ASD). This document also provides guidance for primary care and non-genetics specialists caring for these patients while awaiting consultation with a clinical geneticist or metabolic specialist.Methods of statement development A multidisciplinary group reviewed existing literature and guidelines on the use of genetic and metabolic investigations for the diagnosis of NDDs and synthesised the evidence to make recommendations relevant to the Canadian context. The statement was circulated for comment to the Canadian College of Medical Geneticists (CCMG) membership-at-large and to the Canadian Pediatric Society (Mental Health and Developmental Disabilities Committee); following incorporation of feedback, it was approved by the CCMG Board of Directors on 1 September 2022.Results and conclusions Chromosomal microarray is recommended as a first-tier test for patients with GDD, ID or ASD. Fragile X testing should also be done as a first-tier test when there are suggestive clinical features or family history. Metabolic investigations should be done if there are clinical features suggestive of an inherited metabolic disease, while the patient awaits consultation with a metabolic physician. Exome sequencing or a comprehensive gene panel is recommended as a second-tier test for patients with GDD or ID. Genetic testing is not recommended for patients with NDDs in the absence of GDD, ID or ASD, unless accompanied by clinical features suggestive of a syndromic aetiology or inherited metabolic disease.